|
|
|
| The pregnancy outcomes,the hormone level and improvement of ovarian function of infertility patients with polycystic ovary syndrome after the treatment of Bushenhuoxue prescription |
| 1.Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, 310053; 2.The Third Affiliated Hospital of Zhejiang Chinese Medical University |
|
|
|
|
Abstract To investigate the effect of Bushenhuoxue prescription for treating patients with polycystic ovary syndrome (PCOS), and to study its improvements of hormone and ovarian function of the patients. Methods: 120 infertility patients with PCOS admitted to hospital from January 2021 to October 2023 were selected and were divided into experimental group and control group according to the double-blind method, with 60 cases in each group. The patients in the control group were treated with clomiphene citrate tablets for 3 menstrual cycles, and the patients in the experimental group were treated with Bushenhuoxue prescription for 3 menstrual cycles. The endometrial receptivity, the follicle development situation, the hormone level, the ovulation rate, and the pregnancy outcomes of the patients in the two groups after treatment were observed. Results: After treatment, the ovulation rate (93.3%) and the pregnancy rate (55.0%) of the patients in the experimental group were significantly higher than those (80.0% and 33.3%) of the patients in the control group, but the spontaneous abortion rate (3.3%) of the patients in the experimental group was lower than that (16.7%) of the patients in the control group. The endometrial thickness (9.36±0.77 mm) of the patients in the experimental group was significantly higher than that (8.42±0.59 mm) of the patients in the control group. The values of uterine artery pulsatility index (2.02±0.21) and uterine artery resistance index (0.59±0.08) of the patients in the experimental group were significantly lower than those (2.31±0.26 and 0.71±0.11) of the patients in the control group. The largest follicle diameter (2.23±0.42 cm) and the number of dominant follicle (2.68±0.51) of the patients in the experimental group were significantly higher than those (1.92±0.40 cm and 2.23±0.42) of the patients in the control group. The number of follicles (19.85±3.98) of the patients in the experimental group was significantly less than that (24.28±4.06) of the patients in the control group. The levels of follicle-stimulating hormone (3.77±0.86 U/L), luteinizing hormone (8.11±2.21 U/L) and testosterone (0.51±0.07 ng/ml) of the patients in the experimental group were significantly lower than those (4.61±0.79 U/L, 9.95±2.61 U/L and 0.64±0.14 ng/ml) of the patients in the control group, but the progesterone level (0.89±0.09 nmol/L) of the patients in the experimental group was significantly higher than that (0.72±0.04 nmol/L) of the patients in the control group (all P<0.05). Conclusion: Bushenhuoxue prescription for treating patients with PCOS is helpful to increase their receptivity of endometrium, to promote their normal development of follicle and to correct sex hormone disorder, to increase their ovulation rate and to improve their pregnancy outcomes, and which has good clinical efficacy.
|
|
|
|
|
|
|
|
|
